Olema Pharmaceuticals (OLMA) investor relations material

Strategic focus and pipeline updates

• Focused on ER-positive, HER2-negative breast cancer, representing 70% of cases globally.

• Lead program palazestrant is a complete estrogen receptor antagonist in two phase 3 trials: OPERA-01 (monotherapy, readout in fall) and OPERA-02 (combo with ribociclib, enrolling now).

• KAT6/7 inhibitor program (OP-3136) progressing, with first monotherapy data expected late Q2, targeting multiple cancers.

• Combination studies with OP-3136 and palazestrant underway, with further data expected later in the year.

• Transitioning to a commercial-stage company, building a U.S. sales force, and seeking global collaborators.

Clinical data and competitive positioning

• Palazestrant shows high exposure, long half-life, strong tolerability, and broad combinability with other agents.

• Phase 2 monotherapy data: 7 months PFS in ESR1 mutant, 5.5 months in wild type, exceeding competitors.

• Combination with ribociclib in first-line post-CDK4/6 setting achieved a year of PFS, supporting OPERA-02.

• KOLs view recent lidERA data as impressive, confirming oral SERDs' potential to advance endocrine therapy.

• Adjuvant study design would likely combine a CDK4/6 inhibitor with a CERAN, prioritizing tolerability.

Market opportunity and financial outlook

• Preparing for U.S. launch of palazestrant, aiming for revenue generation and potential cash flow positivity post-launch as early as next year.

• Second/third-line setting for palazestrant combinations could represent a $5–10 billion market; first-line exceeds $10 billion.

• Management changes reflect the shift to commercialization, seeking leaders with launch experience.

• Collaborations, such as with Novartis for OPERA-02, help offset trial costs.